CytoPathfinder
Tokyo, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
CytoPathfinder develops and commercializes solid-phase transfection technology to simplify and improve gene function analysis for drug discovery and cell therapy research.
Oncology
Technology Platform
Solid-phase transfection technology that pre-coats nucleic acids, transfection reagents, and patented accelerator compounds on microplate surfaces, enabling simplified and efficient gene delivery to difficult-to-transfect cells including primary cells and stem cells.
Opportunities
Expansion into cell therapy applications with large-volume culture plates and increased adoption in pharmaceutical high-throughput screening workflows represent significant growth potential.
Risk Factors
Competition from established liquid-phase transfection reagent companies and the need to continuously demonstrate superior performance across diverse cell types in a rapidly evolving research tools market.
Competitive Landscape
Competes against major transfection reagent providers like Thermo Fisher and Promega, but differentiates through solid-phase technology that simplifies protocols and improves efficiency with difficult primary cells and stem cells.